 |
|
|
|
 |
|
July 18, 2006
In this session, Elan and Wyeth bring together academic and industry experts from around the world to present a comprehensive overview of immunotherapy-related research in Alzheimer's disease. Addressing research in both the laboratory and the clinic, this symposium is a unique opportunity for the scientific community to learn more about current programs and projects that may represent new hope for the Alzheimer's community. Chaired by Dale Schenk, PhD, Chief Scientific Officer, Elan, and Menelas Pangalos, PhD, Vice President, Neuroscience Discovery, Wyeth Research, the symposium will address a broad range of topics in immunotherapy.
Chairs:
Dale Schenk, PhD, Chief Scientific Officer, Elan
Menelas Pangalos, PhD, Vice President, Neuroscience Discovery, Wyeth Research
|
|
|
|
|
|
Long Term Outcomes of Participants in the AN1792 (synthetic A-Beta) Phase II Immunotherapy Trial
Speaker: Leon Thal, MD, Professor, Department of Neurosciences, University of California, San Diego |
|
|
|
|
|
Immunotherapy for AD: Further Insights From Model Systems
Speaker: Peter Seubert, PhD, Vice President, Neurodegenerative Research, Elan |
|
|
|
|
|
PAI - 1 Inhibitors Lead to the Proteolytic Clearance of A-Beta
Speaker: Steven Jacobsen, PhD, Associate Director, Neuroscience Discovery, Wyeth Research
|
|
|
|
|
|
Beta- and Gamma-Secretases as Therapeutic Targets
Speaker: Mark Shearman, PhD, Senior Director, Neuroscience Drug Development, Merck |
|
|
|
|
|
Can Amyloid Imaging Facilitate Progress on Anti-Amyloid Therapies in AD?
Speaker: William Klunk, MD, PhD, Associate Professor of Psychiatry and Neurology, University of Pittsburgh |
|
|
|
|
|
Archive |
 |
|
|
